Cancer stem-neuroendocrine cells in an atypical carcinoid case report. by MASCIALE, VALENTINA et al.
© Translational lung cancer research. All rights reserved.   Transl Lung Cancer Res 2019;8(6):1157-1162 | http://dx.doi.org/10.21037/tlcr.2019.12.07
Introduction
Although lung neuroendocrine tumors (NETs) are 
considered a distinct family of lung tumors (1), there is 
evidence suggesting that typical carcinoid tumors (TCs) and 
atypical carcinoid tumors (ACs) are morphologically distinct 
from large-cell neuroendocrine carcinomas (LCNECs) 
and small-cell lung cancer (SCLC) (1). Lung NETs can 
be classified as well-differentiated (low-grade typical 
carcinoids and intermediate-grade atypical carcinoids) and 
poorly differentiated (high-grade large-cell neuroendocrine 
carcinoma or SCLC) (2). The World Health Organization 
(WHO) classification of lung NETS was updated in 2015 
and organized the types of lung NETs on a spectrum (3). 
However, the most important point of differentiation 
analysis is the dichotomous distinction between tumors 
that are low-grade (typical carcinoid and atypical carcinoid) 
and high-grade (large-cell neuroendocrine and small-cell 
carcinomas) (4,5). In particular, with regards of low- and 
intermediate-grade NETS, the differences are mainly based 
on the number of mitoses (2).
The staging of lung NETs is based on the TNM 
staging of non-NET lung cancers, which adheres to the 
current WHO classification system (6). Given that many 
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lung carcinoids and atypical carcinoids are larger than 
3 cm, this staging system is not ideal for this subset of lung 
malignancies (7). In fact, 5% to 20% of TCs and 30% to 
40% of ACs metastasize, and many patients present with 
recurrent disease or metastases to the liver or bone (8). 
As a result, delays in diagnosis increase the probability of 
developing metastatic disease, which has a negative impact 
on prognosis (8). One of the main points that remains 
unclear is cell composition of these tumors. 
Our report suggests that there is a large cancer stem cells 
(CSCs) subpopulation in carcinoid tumors. We speculate 
that this elevated percentage of CSCs may be related to 
the aggressiveness of the tumor, as represented by the 
characteristics of this intermediate grade tumor which tends 
to metastasize.
This new finding represents an important aspect in 
the definition of future markers even for neuroendocrine 
tumors with diagnostic and therapeutic purposes.
Methods
Case presentation
We present a case of 58-year-old woman who came 
to our attention for a chest X-ray accidental finding, 
due to recurrent fever episode, of a 2 cm nodule at the 
level of the basal segment of the right lower lobe of 
the lung. Chest CT with enhancement confirmed the 
presence of a solid formation in the right lower lobe and 
a 18F-fluorodesossiglucose positron emission tomography 
(18F-FDG PET) showed a mild hypermetabolic lesion 
(SUVmax 2.5), very suspicious for carcinoid tumor (Figure 1). 
Preoperative assessment and pulmonary function test 
Figure 1 Lesion of the right lower lobe. 18F-FDG PET showed a mild hypermetabolic nodule (SUVmax =2.5). 18F-FDG PET, 
18F-fluorodesossiglucose positron emission tomography.
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were in normal ranges. In February 2018, the patient was 
undergone right lower lobectomy by lateral thoracotomy. 
The intraoperative histological examination described 
cells highly suspicious for neuroendocrine tumor, which 
was confirmed later by the diagnosis of atypical carcinoid 
of the lung, with mitotic activity equal to 2 for 10HPF. 
Immunohistochemistry was positive for chromogranin, 
CD56, synaptophysin and negative for TTF1.
Cells extraction and fluorescence-activated cell sorting 
(FACS) analysis 
Tumor tissue was washed in sterile Dulbecco’s PBS (L1825-
BC, Merck Millipore) and mechanically minced into 
small pieces (2 to 4 mm), further digested using a tumor 
dissociation kit in a disposable gentle MACS™ C-Tube 
(Miltenyi) according to the manufacturer’s instructions. 
Samples were digested for 60 min at 37 ℃ in a gentle MACS 
Octo dissociator and filtered through 70-μm sterile cell 
strainers, centrifuged at 300 ×g for 5 min, and resuspended 
in a DMEM and HAM’S F12 media mixture (2:1) (Gibco) 
containing 50 IU/mL penicillin-streptomycin and 4 mM 
glutamine. Single-cell suspensions of the primary tumor 
cells were diluted in ALDEFLUOR assay buffer containing 
BODIPY-aminoacetaldehyde (STEMCELL Technologies, 
Vancouver, BC). Cell morphology was evaluated using side 
scatter (SSC) and forward scatter (FSC). Dead cells were 
excluded using 7-AAD (7-amino-actinomycin D) staining. 
Cell sorting and ALDH analysis were performed using a 
FACS-ARIA III (Becton Dickinson, Franklin Lakes, NJ). 
The results were analyzed using FACS Diva software 
(Becton Dickinson). The gating strategy included the 
ALDHhigh gate, which was set at least one log apart from the 
ALDHlow gate. 
Immunohistochemistry
Patient’s slides were deparaffinized, rehydrated and then 
washed in PBS. Sodium citrate buffer was used for antigen 
retrieval. Samples were incubated with the anti-SOX2 
(1:200) (MA1-014 Thermo Fisher Scientific, Meridian 
Road Rockford, IL, USA), overnight at 4 ℃. Images were 
collected and the positivity evaluated using a Zeiss Axioskop 
microscope with a Zeiss AxioCam ICc 3 High-Resolution 
Microscope Camera.
Results
Clinical conditions from surgery
No complications were shown during and after the 
operation. The patient was discharge from Hospital after 
6 days from surgery. A chest X-ray at 6 and 30 days from 
surgery was negative for lesions or pleural-parenchyma 
alterations. The oncologist suggested to proceed with 
monitoring through follow up.
ALDHhigh stem cells were identified in primary cells of 
atypical carcinoid of the lung 
Tumor tissue dissociation efficiently released cancer cells 
characterized by a heterogeneous morphology, as illustrated 
in the widespread FSC and SSC values (Figure 2). The mean 
viability of the samples was 99.7% based on 7-AAD staining. 
These data further confirmed that the developed dissociation 
procedure was a non-toxic approach to isolating cells from 
tumor tissues. The CSCs were physically separated from the 
bulk parental tumor cells and recovered by FACS according 
to the following gating strategy. Tumor cells were first 
identified based on their morphological parameters (FSC/
SSC), and ALDH activity was measured in the 7-AAD 
negative cell population only (Figure 2). ALDHlow and 
ALDHhigh cells were both selected and sorted (Figure 2). An 
ALDHhigh subpopulation was the 53.10% of all viable lung 
cancer cells, which indicates that more than half of the entire 
tumor cell population was composed by CSCs.
Immunohistochemical evaluation of the SOX2 stem cell 
marker in atypical lung cancer cells 
To further evaluate the stemness of the cells extracted 
from the tumor biopsy, SOX2 immunohistochemistry 
was performed. Tissue sections were examined at 10× 
magnification to characterize the overall staining pattern 
and at 20× and 40× magnification for a more accurate 
evaluation of the positivity of the cells, represented by 
brown nuclei. As expected by FACS analysis, about a half of 
the nuclei of the cells were positive for SOX2 (Figure 3).
Discussion
In our case, we show the presence of similar percentage 
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Figure 2 FACS analysis. Cytofluorimetric analysis of ALDHhigh cells in atypical carcinoid primary cells. FACS, fluorescence-activated cell 
sorting.
Figure 3 Immunohistochemistry of lung atypical carcinoid. Anti-SOX2 monoclonal antibody of tumor slides. Representative images were 
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of CSCs by cytofluorimetric and immunohistochemistry 
analysis as first finding in the knowledge of atypical 
carcinoids tumors. This aspect is very important suggesting 
a new characterization of neuroendocrine tumors. We used 
ALDH for cytofluorimetric analysis and SOX2 marker for 
immunohistochemistry, which are the most representative 
markers for CSCs (9) and we noted a very high percentage 
of CSCs comparable between the two techniques. In 
particular, the 50% of ALDH positivity through the 
cytofluorimetric analysis was found. As previously 
described, aldehyde dehydrogenase (ALDH) is an enzyme 
that participates in important cellular mechanisms as 
aldehyde detoxification and retinoic acid synthesis; 
moreover, ALDH activity is involved in drug resistance, a 
characteristic of CSCs (10). Even though ALDH is found in 
stem cells, CSCs and progenitor cells, this enzyme has been 
successfully used to identify and isolate cell populations 
with CSC properties from several tumor origins (11). In 
fact, in 2010 Sullivan et al. identified CSCs in a panel of 11 
NSCLC tumor samples, 45 NSCLC lines, and 7 SCLC 
lines that are used to study ALDH activity and sorted a 
subpopulation of NSCLC stem-like cells dependent on 
Notch signaling (12). As previously described, SCLC is a 
high-grade SCLC which is part of lung NET. However, 
nobody at this time has previously described the presence of 
CSCs in carcinoid tumors (13).
As previously described, ALDH+ population in NSCLC 
is usually not represented by a high percentage of CSCs, 
which is normally not more than 5% (12). In particular, 
Huang et al. (14) analyzed in H28, H2052 lung metastatic 
cells lines a sub-population of chemoresistant cells by 
using ALDH as CSC markers and observed an ALDH+ 
expression in H28 of 2.29%±1.6%, and in H2052 of 
0.82±0.32. Moreover, Bayat Mokhtari et al. (15) in bronchial 
carcinoid cell lines was observed an ALDH+ expression that 
reach at least 1%.
We share this concept for the first time with this 
message: if the presence of CSCs will be confirmed at high 
percentage in more cases, that will be the basement for 
a new definition of pathological markers as well as new 
molecular findings for neuroendocrine tumors.
Beside the limitation of a single case, we strongly 
support the hypothesis of the presence of cancer stem-
neuroendocrine cells (CSCs-NETs) as subpopulation in 
these types of tumors. In conclusion, we may speculate that 
the different aggressiveness of the atypical versus the typical 
carcinoid could be derived not only from the number of the 
mitosis but also from the percentage of CSCs. However, 
translational studies are mandatory in the future to 
investigate the morphologic cells characterization as well as 
also the stemness genes recognition.
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